Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Receivables (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Change in Receivables data on record, last reported at -$1.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 989.05% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached $5.2 million, up 224.1%, while the annual FY2025 figure was $5.2 million, 224.1% up from the prior year.
  • Change in Receivables reached -$1.8 million in Q4 2025 per VRCA's latest filing, up from -$2.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.6 million in Q1 2025 and bottomed at -$10.2 million in Q3 2024.
  • Average Change in Receivables over 3 years is $487200.0, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Change in Receivables: skyrocketed 333.72% in 2024, then plummeted 989.05% in 2025.
  • A 3-year view of Change in Receivables shows it stood at -$86000.0 in 2023, then soared by 333.72% to $201000.0 in 2024, then tumbled by 989.05% to -$1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$1.8 million in Q4 2025, -$2.1 million in Q3 2025, and $3.6 million in Q2 2025.